Target Price | $762.52 |
Price | $578.05 |
Potential | 31.91% |
Number of Estimates | 30 |
30 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $762.52. This is 31.91% higher than the current stock price. The highest price target is $1,063.65 84.01% , the lowest is $548.43 5.12% . | |
A rating was issued by 34 analysts: 27 Analysts recommend Regeneron Pharmaceuticals to buy, 6 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 31.91% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
29 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $14.1b . This is 0.47% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $15.3b 7.49% , the lowest is $13.1b 7.96% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $14.1b | 0.39% |
2026 | $14.8b | 4.74% |
2027 | $16.4b | 10.70% |
2028 | $17.6b | 7.20% |
2029 | $18.7b | 6.07% |
2030 | $19.5b | 4.74% |
2031 | $20.0b | 2.59% |
2032 | $19.7b | 1.54% |
15 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.6b . This is 0.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.3b 37.21% , the lowest is $3.1b 31.57% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 1.17% |
---|---|---|
2025 | $4.6b | 2.68% |
2026 | $5.3b | 14.80% |
2027 | $6.0b | 14.78% |
2028 | $7.1b | 17.75% |
2029 | $7.6b | 6.95% |
2030 | $8.0b | 5.63% |
2031 | $8.4b | 4.99% |
2032 | $6.7b | 20.03% |
2024 | 33.10% | 8.72% |
---|---|---|
2025 | 32.34% | 2.30% |
2026 | 35.45% | 9.62% |
2027 | 36.75% | 3.67% |
2028 | 40.37% | 9.85% |
2029 | 40.70% | 0.82% |
2030 | 41.04% | 0.84% |
2031 | 42.00% | 2.34% |
2032 | 34.11% | 18.79% |
30 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $4.2b . This is 5.01% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 6.24% , the lowest is $3.6b 19.74% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.4b | 11.61% |
---|---|---|
2025 | $4.2b | 4.02% |
2026 | $4.5b | 5.53% |
2027 | $5.4b | 19.83% |
2028 | $5.9b | 10.02% |
2029 | $6.4b | 9.28% |
2030 | $7.0b | 8.36% |
2031 | $7.4b | 5.95% |
2032 | $7.2b | 2.70% |
2024 | 31.07% | 3.08% |
---|---|---|
2025 | 29.94% | 3.64% |
2026 | 30.17% | 0.77% |
2027 | 32.65% | 8.22% |
2028 | 33.51% | 2.63% |
2029 | 34.52% | 3.01% |
2030 | 35.72% | 3.48% |
2031 | 36.89% | 3.28% |
2032 | 36.45% | 1.19% |
30 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $39.81 . This is 3.02% lower than earnings per share in the financial year 2024. The highest EPS forecast is $44.52 8.45% , the lowest is $33.63 18.08% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $39.81 | 3.83% |
2026 | $42.01 | 5.53% |
2027 | $50.34 | 19.83% |
2028 | $55.38 | 10.01% |
2029 | $60.52 | 9.28% |
2030 | $65.58 | 8.36% |
2031 | $69.48 | 5.95% |
2032 | $67.61 | 2.69% |
Current | 14.08 | 44.47% |
---|---|---|
2025 | 14.52 | 3.11% |
2026 | 13.76 | 5.23% |
2027 | 11.48 | 16.57% |
2028 | 10.44 | 9.06% |
2029 | 9.55 | 8.52% |
2030 | 8.81 | 7.75% |
2031 | 8.32 | 5.56% |
2032 | 8.55 | 2.76% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 3.99 and an P/S ratio of 4.33 .
This results in the following potential growth metrics and future valuations:
Current | 3.98 | 47.42% |
---|---|---|
2025 | 3.99 | 0.35% |
2026 | 3.81 | 4.52% |
2027 | 3.44 | 9.67% |
2028 | 3.21 | 6.72% |
2029 | 3.03 | 5.73% |
2030 | 2.89 | 4.52% |
2031 | 2.82 | 2.52% |
2032 | 2.86 | 1.56% |
Current | 4.31 | 46.69% |
---|---|---|
2025 | 4.33 | 0.48% |
2026 | 4.13 | 4.52% |
2027 | 3.74 | 9.67% |
2028 | 3.48 | 6.72% |
2029 | 3.28 | 5.73% |
2030 | 3.14 | 4.52% |
2031 | 3.06 | 2.53% |
2032 | 3.10 | 1.56% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Oct 14 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 13 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 10 2025 |
Jefferies |
Buy
➜
Buy
|
Unchanged | Aug 27 2025 |
Bernstein |
Outperform
➜
Outperform
|
Unchanged | Aug 27 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 11 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Aug 04 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Oct 14 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 13 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 10 2025 |
Unchanged
Jefferies:
Buy
➜
Buy
|
Aug 27 2025 |
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Aug 27 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 11 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Aug 04 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.